Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2006-07-18
2006-07-18
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S395000, C514S415000, C514S712000, C544S253000, C544S282000, C548S306400, C549S362000, C549S469000, C568S058000
Reissue Patent
active
RE039197
ABSTRACT:
The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
REFERENCES:
patent: 4973599 (1990-11-01), Gilman et al.
patent: 5028629 (1991-07-01), Hite et al.
patent: 5208253 (1993-05-01), Boschelli et al.
patent: 5776951 (1998-07-01), Arrowsmith et al.
patent: 5817862 (1998-10-01), Poetsch et al.
patent: 5883106 (1999-03-01), Stevens et al.
patent: 5883133 (1999-03-01), Schwark et al.
patent: 5912266 (1999-06-01), Perez
patent: 6329362 (2001-12-01), Archibald et al.
patent: 2245586 (1997-08-01), None
patent: 2123383 (1971-12-01), None
patent: 0219756 (1986-10-01), None
patent: 835 867 (1998-04-01), None
patent: 887 340 (1998-12-01), None
patent: 2 117 760 (1983-10-01), None
patent: 62012757 (1987-01-01), None
patent: 12072766 (2000-03-01), None
patent: WO98/13347 (1998-02-01), None
patent: WO98/39303 (1998-09-01), None
patent: WO98/54207 (1998-12-01), None
patent: WO99/11258 (1999-03-01), None
patent: WO99/20617 (1999-04-01), None
patent: WO99/20618 (1999-04-01), None
patent: WO99/49856 (1999-10-01), None
patent: WO00/15604 (2000-03-01), None
patent: WO00/15645 (2000-03-01), None
patent: WO00/21920 (2000-04-01), None
patent: WO00/48989 (2000-08-01), None
patent: WO01/06984 (2001-02-01), None
patent: WO01/07052 (2001-02-01), None
patent: WO01/27102 (2001-04-01), None
Springer, T.A., 1994, Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm, CELL, 76: 301-314.
Lawrence, M.B., Springer, T.A., 1991, Leukocytes' Roll on a Selectin in Physiologic Flow Rate: Distinction from and Prerequisite for Adhesion Through Integrins, CELL, 65:859-873.
Von Adrian, V., Chambers, J.D., McEnvoy, L.M. Bargatze, R.F., Arfos, K.E., Butcher, E.C., 1991, Two-Step Model of Leukocyte-Endothelial Cell Interactions in Inflammation, Proc. National Acad. Sci USA, 88:7538-7542.
Ley, K., Gaehtgens, P., Fennie, C., Singer, M.S., Lasky, L.H., Rosen, S.D., 1991, Lectin-Like Cell Adhesion Molecule 1 Mediates Rolling in Mesenteric Venules, in vivo, BLOOD, 77:2553-2555.
Higuchi, T., Stella, V., Pro-drugs as Novel Delivery Systems, vol. 14 of the A.C.S. Symposium Series, (1993).
Roche, E.B., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987.
Prescott, E., Methods in Cell Biology, vol. XIV, Academic Press, New York, NY (1976), p. 33 et seq.
Berge, S.M., et al. J. Pharmaceutical Sciences, 1977, 66:1 et seq.
Kakimoto, et al., Cell Immunol 142:326-337, 1992.
Knoerzer, et al., Toxical Pathol 25:13-19, 1997.
Schimmer, et al., J. Immunol 160: 1455-1477, 1998.
Oppenheimer-Marks, et al., J. Clin. Invest 101: 1261-1272, 1998.
Wegner, et al., Science 247:456-459, 1990.
Bloemen, et al., Am J. Respir Crit Care Med 153:521-529, 1996.
Wegner, et al., Lung 170: 267-279, 1992.
Mulligan, et al., J Immunol 154:1350-1363, 1995.
Nagase, et al., Am J Respir Crit Care Med 154:504-510, 1996.
Bennet, et al., J Pharmacol Exp Ther, 280:988-1000, 1997.
Hasagawa, et al., Int Immunol, 6:831-838, 1994.
Herrold, et al., Cell Immunol, 157:489-500, 1994.
Tanaka, et al., J. Immunol, 151:5088-5095, 1993.
Kawasaki, et al., J. Immunol, 150:1074-1083, 1993.
Panes, et al., Gastroenterology, 108:1761-1769, 1995.
Hallahan, et al., Proc Natl Acad Sci USA, 94:6432-6437, 1997.
Tamiya, et al., Immunopharmacology, 29(1):53-63, 1995.
Hartman, et al., Cardiovasc Res, 30(1):47-54, 1995.
DeMeester, et al., Transplantation, 62(10): 1477-1485, 1996.
Horgan, et al., Am J Physiol, 261(5):H1578-H1584, 1991.
Bowes, et al., Exp Neurol, 119(2):215-219, 1993.
Chopp, et al., Stroke, 25(4):869-875, 1994.
Clark, et al., Neurosurg, 75(4): 623-627, 1991.
Gute, et al., Mol Cell Biochem, 179: 169-187, 1998.
Isobe, et al., Science, 255: 1125-1127, 1992.
Talento, et al., Transplantation, 55: 418-422, 1993.
Cosimi, et al., J. Immunol, 144: 4606-4612, 1990.
Nakao, et al., Muscle Nerve, 18:93-102, 1995.
Gorczynski, Wojcik, J. Immunol, 152:2011-2019, 1994.
He, et al., Opthalmol Vis Sci, 35: 3218-3225, 1994.
Zeng, et al., Transplantation, 58: 681-689, 1994.
Harning, et al., Transportation, 52: 842-845, 1991.
Aoudjit, et al., J. Immunol, 161: 2333-2338, 1998.
Gross, et al., Science 281, 703-706, 1998.
Ali, H. et al.,Mechanisms of Inflammation and Leukocyte Activation,Med. Clin. North America (1997) 81:1-28.
Aoudjit, et al., J. Immunol. (1998) 161: 2333-2338.
Bella, J., et al.,The Structure of the Two Amino-terminal Domains of Human ICAM-1 Suggests How it Functions as a Rhinovirus Receptor and As An LFA-1 Integrin Ligand,Proc. Natl. Acad. Sci., USA (1998) 95:4140-4145.
Bennet, et al.,An ICAM-1 Antisense Oligonucleotide Prevents and Reverses Dextran Sulfate Sodium-Induced Colitis in Mice,J. Pharmacol. Exp. Ther. (1997) 280:988-1000.
Berge, S.M., et al.,Pharmaceutical Salts,J. Pharmaceutical Sciences (1977) 66:1 et seq.
Binnerts, M.E., et al.,How LFA-1 Binds to Different Ligands,Immunol. Today (1999) 20:240-245.
Bloemen, et al.,LFA-1, and not Mac-1, is Crucial for the Development of Hyperreactivity in a Murine Model of Nonallergic Asthma,Am. J. Respir. Crit. Care Med. (1996) 153:521-529.
Boschelli, D.H., et al.,Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo[b]thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent,J. Med. Chem. (1995) 38:4597-4614.
Bowes, et al.,Monoclonal Antibody to the ICAM-1 Adhesion Site Reduces Neurological Damage in a Rabbit Cerebral Embolism Stroke Model,Exp. Neurol. (1993) 119(2):215-219.
Carlos, T.M.,Leukocyte-Endothelial Adhesion Molecules,Blood (1994) 84:2068-2101.
Chemical Abstracts (1987) 106:23, Abstract No. 196262.
Chopp, et al.,Postischemic Administration of an Anti-Mac-1 Antibody Reduces Ischemic Cell Damage After Transient Middle Cerebral Artery Occlusion in Rats,Stroke (1994) 25(4):869-875.
Clark, et al.,Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule,Neurosurg. (1991) 75(4): 623-627.
Cosimi, et al.,In Vivo Effects of Monoclonal Antibody to ICAM-1(CD54)In Nonhuman Primates with Renal Allografts,J. Immunol. (1990) 144: 4606-4612.
DeMeester, et al.,Attenuation of Rat Lung Isograft Reperfusion Injury with a Combination of Anti-ICAM-1 and Anti-β2Integrin Monoclonal Antibodies,Transplantation (1996) 62(10): 1477-1485.
Edwards, C.P. et al.,Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-associated Antigen-1,J. Biol. Chem. (1998) 273:28937-28944.
Emeigh, J.E., et al.,Small Molecule Antagonists of LFA-1-Mediated Cell Adhesion,221st ACS National Meeting, San Diego, CA, USA (2001) MEDI 256.
Fisher, K.L., et al.,Identification of the Binding Site in Intercellular Adhesion Molecule 1 for its Receptor, Leukocyte Function-associated Antigen 1,Mol. Biol. Cell (1997) 8:501-515.
Franke et al.,Synthetische Juvenihormone,Helvetica Chimca Acta (1975) 58(32):268-278.
Gadek, T.R., et al.;Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein—Protein Interaction as Novel Immunomodulatory Agents,220th ACS National Meeting, Washington, D.C., USA (2000) MEDI 177.
Gahmberg, C.G.,Leukocyte Adhesion: CD11/CD18 Integrins and Intercullular Adhesion Molecules,Curr. Opin. Cell Biol. (1997) 9:643-650.
Gahmberg, C.G.,Leukocyte Adhesion: Structure and Function of Human Leukocyte β2-integrins and Their Cellular Ligands,Eur. J. Biochem. (1997) 245:215-232.
Gorczynski, Wojcik,A Role for Nonspecific(Cyclosporin A)or Specific(Monoclonal Antibodies to ICAM-1, LFA-1, and IL-10)Immunomodulation in the Prolongation of Skin Allografts After Antigen-Specific Pretransplant Immunization or Transfusion,J. Immunol. (1994) 152:2011-2019.
Green, J.M.,T Cell Receptor Stimulation, But Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events,Eur. J. Immunology (1994) 24:265-272.
Gross, et al.,Identification of LFA-1 as a Candidate Autoantigen in Treatm
Geldern Tom von
Link James T.
Liu Gang
Pei Zhonghua
Winn Martin
Abbott Laboratories
Finnegan Henderson Farabow Garrett & Dunner LLP
Shameem Golam M. M.
LandOfFree
Cell adhesion-inhibiting antiinflammatory and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell adhesion-inhibiting antiinflammatory and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell adhesion-inhibiting antiinflammatory and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557469